"There is now very clear evidence that this drug saves lives in bleeding trauma patients," said Ian Roberts, lead study author and professor of public health at the London School of Hygiene and Tropical Medicine. "Patients in car crashes, patients who are shot or stabbed. Or it could be a soldier in places like Afghanistan and Iraq."
Utilizing tranexamic acid to deal with patients within the wake of traumatic injury inflicting large bleeding could save about 2,000 lives annually within the United States alone, said Roberts - even more worldwide. The issue, he says, is that few doctors are aware of evidence suggesting the treatment works.
"This treatment could save between seventy and one hundred thousand lives a year if doctors knew about it," said Roberts. "A lot of people will find it a really strange idea that a treatment shown to be effective is not being used."
Tranexamic acid belongs to a group of drugs called antifibrinolytics, medicine that inhibit blood clots from dissolving. When a patient is bleeding profusely, there are two processes within the body occurring simultaneously, said Roberts - clot formation and clot breakdown. While the body struggles to form clots, and thereby stanch bleeding, there are competing enzymes produced in the body that break down clots.
"We don't want [to break down clots] when we're bleeding to death," said Roberts. "We want all the clotting we can get."
This most recent research about tranexamic acid, printed by the Cochrane Library, is based totally on knowledge from a 2010 research referred to as CRASH-2. The study concerned 20,211 trauma patients in a number of countries who had, for example, been shot, stabbed or involved in a automobile crash - or who had been at some other risk for significant bleeding. Patients who received tranexamic acid were 15% less prone to bleed to death - and fewer more likely to die, period - than those who received placebo.
Roberts was the chief investigator for the CRASH-2 trial which was funded, partially, by one of the makers of tranexamic acid, Pfizer.
In prescribing info by Pfizer for Cyklokapron, a brand of tranexamic acid used to prevent bleeding in hemophiliacs following tooth extraction, dangers in animals (given much higher doses of tranexamic acid than humans typically receive) include retinal abnormalities.
"No retinal changes have been reported or noted in eye examinations in patients treated with tranexamic acid for weeks to months in clinical trials," according to prescribing information issued by Pfizer. "However, visual abnormalities, often poorly characterized, represent the most frequently reported postmarketing adverse reaction in Sweden."
And prescribing data for Lysteda, the drug used to treat heavy menstrual bleeding, describes reports of deep vein thrombosis and visual disturbances.
"We found no evidence of adverse effects" during the CRASH-2 trial, said Roberts.
Researchers plan to check tranexamic acid as a potential treatment for excessive bleeding after childbirth and to quell bleeding after traumatic brain injury.
